GlobeNewswire

LeoVegas publishes prospectus and new financial information in connection with application of admission to trading on Nasdaq Stockholm

Dela

LeoVegas AB (publ) (" LeoVegas ") has to Nasdaq Stockholm AB applied for admission to trading of LeoVegas' shares on the regulated market Nasdaq Stockholm. The Board of Directors of LeoVegas have in connection with the listing on Nasdaq Stockholm prepared a prospectus that today has been approved and registered by the Swedish Financial Supervisory Authority. The prospectus contains, due to regulatory requirements, new financial information as of 31 October 2017 attributable to LeoVegas' capital structure that has not previously been published. LeoVegas expects a formal approval from Nasdaq Stockholm at the latest by 31 January 2018.

The prospectus
The prospectus has been prepared in connection with the application of change in listing from Nasdaq First North Premier to Nasdaq Stockholm. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and published on www.leovegasgroup.com. The prospectus will also within a few days be available on the Swedish Financial Supervisory Authority's web page, www.fi.se.

New financial information
The prospectus includes updated information as of 31 October 2017 attributable to LeoVegas' capital structure. This is due to regulatory requirements which implies that financial information attributable to the capital structure may not be older than 90 days upon the date of the prospectus. This information has previously not been published and the table presented below reproduces this information. The tables only include interest-bearing debts. In essence, the financial figures below reflect what was published in LeoVegas' interim-report for the period 1 January - 30 September 2017.

The tables of equity and liabilities as well as net indebtedness can be found on page 64 of the prospectus.

KEUR 31 Oct 2017 Proforma [1]
Current debt    
Guaranteed - -
Secured - -
Unguaranteed/Unsecured - -
Total Current debt - -
     
KEUR    
Non-Current debt    
Current debt - -
Guaranteed - -
Secured - 75 000
Total Non-Current debt - 75 000
     
Shareholder's equity    
Share capital 1 196   1 196 
Legal Reserve 36 588    36 588 
Other Reserves 19 610    19 610 
Total Shareholders' equity   57 394    57 394 

KEUR 31 Oct 17 Proforma [2]
(A) Cash 63 566  34 580
(B) Cash equivalent -
(C) Trading securities -5 399  -7 699
(D) Liquidity (A)+(B)+(C) 58 167  26 881
     
(E) Current Financial Receivable  - -
     
(F) Current Bank debt  - -
(G) Current portion of non current debt - -
(H) Other current financial debt - -
(I) Current Financial Debt (F)+(G)+(H) - -
     
(J) Net Current Financial Indebtedness (I)-(E)-(D) -58 167  -26 881 
     
(K) Non current Bank Loans - -75 000
(L) Bonds Issued  -
(M) Other non current loans  -
     
(N) Non current Financial Indebtedness (K)+(L)+(M) - -75 000
     
(O) Net Financial Indebtedness (J)+(N) -58 167  -101 881 

The prospectus also includes consolidated pro forma financial statements for LeoVegas regarding the acquisition of Royal Panda and Rocket X including a consolidated pro forma income statement for the period January 2017 - September 2017 and a consolidated pro forma balance sheet as of 30 September, 2017.

Trading on Nasdaq Stockholm
LeoVegas expects a formal approval from Nasdaq Stockholm at the latest AB on by 31 January 2018. Provided that an approval is obtained, the last day of trading on First North Premier is expected to be on 2 February 2018, and the first day for trading on Nasdaq Stockholm is planned to commence on 5 February 2018. LeoVegas' shares will be traded under the same ticker (LEO) and ISIN code (SE0008091904). LeoVegas shareholders do not need to take any action in connection with the change in listing.

Adviser
Baker McKenzie is acting as legal adviser to LeoVegas in connection with the change in listing to Nasdaq Stockholm.

For further information, please contact:

Gustaf Hagman, Group CEO co-founder: +46 70 880 55 22, gustaf.hagman@leovegas.com
Philip Doftvik, Head of Investor Relations: +46 73 512 07 20, philip.doftvik@leovegas.com
Visitors address: Luntmakargatan 18, Stockholm
Corporate identity number: 556830-4033

About the LeoVegas mobile gaming group
LeoVegas' passion is "Leading the way into the mobile future". LeoVegas is Sweden's premier GameTech company and is at the forefront of using state-of-the-art technology for mobile gaming. In 2017 the company passed the threshold for being classified as a unicorn, i.e., a start-up valued at more than USD 1 billion. A large part of this success can be credited to an extreme product and technology focus coupled with effective and data-driven marketing. Technology development is conducted in Sweden, while operations are based in Malta. LeoVegas offers casino, live casino and sport gaming, and operates two global and scalable brands - LeoVegas and Royal Panda. The company's shares are listed on Nasdaq First North Premier, and Avanza Bank AB is the company's Certified Adviser. For more about LeoVegas, visit  www.leovegasgroup.com .



[1] This information is presented as a result of the acquisitions of Royal Panda and Rocket X which occurred after 31 October 2017.  

[2] This information is presented due to of the acquisitions of Royal Panda and Rocket X which occurred after 31 October 2017.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LeoVegas AB via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer25.3.2019 11:00:00 CETPressmeddelande

STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief Medical Officer (CMO). Dr. Attar joins Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of Idhifa and Tibsovo for patients with relapsed/refractory Acute Myeloid Leukemia (AML). Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. "Dr. Attar's deep medical and biotech industry experiences will strengthen our clinical development efforts as we continue to advance our first-in-class p53 reactivating agents in late-stage clinical studies", states Christian S. Schade, Pr

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum